$Palvella Therapeutics (PVLA.US)$
Groundbreaking Research Uncovers 93,000 Lymphatic Malformation Cases in U.S. - First Complete Analysis

$Palvella Therapeutics (PVLA.US)$
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Palvella Therapeutics (PVLA) has been granted its fifth U.S. patent (No. 12,268,673) for QTORIN™ rapamycin, extending patent protection until 2038. The patent broadens protection for QTORIN™ 3.9% rapamycin anhydrous gel and its clinical applications in treating microcystic lymphatic malformations (LMs).
QTORIN™ rapamycin has rec...

$Palvella Therapeutics (PVLA.US)$
FDA Breakthrough Therapy Gets Extended Patent Protection for Rare Disease Treatment Until 2038

$Palvella Therapeutics (PVLA.US)$
Breakthrough Treatment Achieves Perfect Response Rate in Rare Disease Trial - FDA Fast Track Drug Shows Promise

$Palvella Therapeutics (PVLA.US)$
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology
Friday, 11th April at 7:30 am
Presentation highlighted the recent expansion of the Phase 3 SELVA trial to include children 3 to 5 years old
Present...

$Palvella Therapeutics (PVLA.US)$
Palvella's $78.9M Cash Injection Powers Rare Disease Drug Development Through 2027

$Palvella Therapeutics (PVLA.US)$
FDA Green-Lights PVLA's Groundbreaking Treatment Trial for Children with Rare Lymphatic Disease

$Palvella Therapeutics (PVLA.US)$
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
Monday, 10th February at 8:00 am
Expansion reflects Palvella's commitment to serving all patients affected by microcystic lymphatic malformations (microcystic LMs)
Company remains on track to report top line resu...

$Palvella Therapeutics (PVLA.US)$ Reuters· 3 mins ago
Palvella Therapeutics Inc - 100% Participants Show Improvement After 12 Weeks of Qtorin Rapamycin

$Palvella Therapeutics (PVLA.US)$
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
3 minutes ago, 5:00 AM PST
Via GlobeNewswire
PVLA
Share
Publication reports 100% of participants were either "Much Improved" or "Very Much Improved" as rated by the Clinician Global Impression of Change following 12-weeks of ...